Share Price | Cognition Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Cognition Therapeutics, Inc.?

Market Cap: As of Jun 18, Cognition Therapeutics, Inc. has a market capitalization of 17.36 million, categorizing it as a Micro Cap.Recent Quarterly Performance: For the latest four quarters, Cognition Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -33.30 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 18.75 million and total assets of 30.23 million.

Q: What does Cognition Therapeutics, Inc. do?

Overview: Cognition Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot: Net Profit: -8 Million (Quarterly Results - Mar 2025) Market Cap: USD 17.36 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.32 Return on Equity: -271.39% Price to Book: 1.41Contact Details: Details: No Company Details Available Registrar Address: Not available.

Q: Is Cognition Therapeutics, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Cognition Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating a positive momentum. The Bollinger Bands also reflect a mildly bullish stance on both weekly and monthly time frames. However, the KST shows a bullish weekly signal but a bearish monthly signal, and the Dow Theory indicates a mildly bearish weekly trend with no trend monthly. The moving averages are mildly bullish on a daily basis. In terms of performance, the stock has significantly outperformed the S&P 500 year-to-date with a return of 109.61% compared to the S&P 500's 12.22%, and over the past year, it has returned 145.37% versus the S&P 500's 17.14%. However, it has underperformed over the last three years with a return of -16.0% compared to the S&P 500's 70.41%. Overall, the current technical stance is mildly bullish, driven by the positive signals from MACD and Bollinger Bands, despite some bearish indicators from KST and Dow Theory.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

612.57 k

Shareholding (Sep 2025)

FII

0.50%

Held by 7 FIIs

DII

89.13%

Held by 6 DIIs

Promoter

6.80%

How big is Cognition Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Cognition Therapeutics, Inc. has a market capitalization of 17.36 million, with net sales of 0.00 million and a net profit of -33.30 million over the last four quarters. The company reported shareholder's funds of 18.75 million and total assets of 30.23 million as of Dec 24.

View full answer

What does Cognition Therapeutics, Inc. do?

22-Jun-2025

Cognition Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $8 million and a market cap of $17.36 million. Key metrics include a negative P/E ratio, a 0.00% dividend yield, and a debt-to-equity ratio of -1.32.

View full answer

Is Cognition Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Cognition Therapeutics, Inc. shows a mildly bullish trend with positive momentum from MACD and Bollinger Bands, despite mixed signals from KST and Dow Theory, while significantly outperforming the S&P 500 year-to-date and over the past year, but underperforming over the last three years.

View full answer

Compare Cognition Therapeutics, Inc. with Similar Stocks

Gain Therapeutics, Inc.Mainz Biomed NV ImmunoPrecise Antibodies Ltd.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 95 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.09

Return on Equity

-76.61%

Price to Book

2.61

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-5 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-19.29%

6 Months

-15.67%

1 Year

148.41%

2 Years

-37.57%

3 Years

-38.25%

4 Years

-62.95%

5 Years

0.0%

Cognition Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-221.19%

EBIT to Interest (avg)

-39.15

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.32

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

22.38%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.61

EV to EBIT

-1.24

EV to EBITDA

-1.25

EV to Capital Employed

-17.81

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-76.61%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

Bullish

No Signal

Bollinger Bands

Mildly Bearish

Bullish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

No Trend

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 5 Schemes (3.57%)

Foreign Institutions

Held by 7 Foreign Institutions (0.5%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 50.51% vs -47.76% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.30",
          "val2": "-14.40",
          "chgp": "56.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.90",
          "val2": "-9.90",
          "chgp": "50.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -31.78% vs -20.56% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-53.70",
          "val2": "-50.50",
          "chgp": "-6.34%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-34.00",
          "val2": "-25.80",
          "chgp": "-31.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]